Cat. No.: HY-N6893

Ergolide

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

Ergolide is an orally active dual inhibitor targeting NF-κB/p65 and NLRP3. Ergolide blocks the NF-κB signaling pathway and the nuclear translocation of p65, and irreversibly binds to the NACHT domain of NLRP3 to inhibit inflammasome assembly. Ergolide significantly reduces the production of inflammatory mediators (e.g., NO, PGE₂) and cytokines, induces cancer cell apoptosis, autophagy and ROS generation. Ergolide also enhances the anti-tumor effect of vincristine. Ergolide alleviates acute lung injury via an NLRP3-dependent mechanism, and effectively improves the survival rate and behavioral function of septic mice and inflammatory zebrafish models. Ergolide is used in the research of metastatic uveal melanoma, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease), sepsis and acute lymphoblastic leukemia.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.48%
CAS No.: 54999-07-4
Formule: C₁₇H₂₂O₅
Masse moléculaire:306.35

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ergolide Chemical Structure

CAS No.: 54999-07-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

p65

NLRP3

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR) :

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	IC₅₀	0.07 μM Compound: 11	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins before LPS challenge measured 24 hrs after LPS challenge by Griess reaction method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins before LPS challenge measured 24 hrs after LPS challenge by Griess reaction method	[PMID: 21924800]
RAW264.7	IC₅₀	3.9 μM Compound: 16	Antiinflammatory action in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 30 mins before LPS challenge measured after 24 hrs by griess reaction Antiinflammatory action in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 30 mins before LPS challenge measured after 24 hrs by griess reaction	[PMID: 21894898]

In Vitro

Ergolide (0.5-10 μM; 96 h) inhibits the metabolism/viability of OMM2.5 metastatic uveal melanoma cells with an IC₅₀ of 2.9 μM, and suppresses the long-term proliferation of both primary (Mel285, Mel270) and metastatic (OMM2.5) uveal melanoma cells^[1].
Ergolide (2.5 μM; 24 h) induces reverse differential expression of BCCIP and CHID1 in OMM2.5 cells and their secreted extracellular vesicles (EVs), upregulating these proteins inside the cells while downregulating them in EVs^[1].
Ergolide (5 μM; 24 h) reduces the production of nitrite, TNFα, IL-6 and MCP1 induced by LTA and LPS in BV2 microglia^[2].
Ergolide (5, 10 μM; 24 h) reduces the viability and enhances the cytotoxicity of human SH-SY5Y neuroblastoma cells; at a concentration of 5 μM, it exacerbates tBHP-induced ROS production in mouse N2a cells and fails to protect SH-SY5Y cells against H₂O₂-induced cell death^[2].
Ergolide (1-5 μM; 30 min) dose-dependently inhibits pyroptosis in mouse bone marrow-derived macrophages (BMDMs) treated with LPS + ATP^[3].
Ergolide (0.5-10 μM; 18 h) reduces the expressions of iNOS, COX-2 proteins and iNOS mRNA in LPS/IFN^--stimulated RAW 264.7 macrophages in a concentration-dependent manner, and inhibits IκB-α degradation after 18 h of incubation^[4].
Ergolide (0-6 μM; 48 h) induces G0/G1 cell cycle arrest in Nalm6 and MOLT-4 acute lymphoblastic leukemia cell lines at 48 h, and upregulates the expression of cell cycle inhibitory genes p21 and p27, with no effect on non-tumorigenic PBMC^[5].
Ergolide (2-4 μM; 24-48 h) induces ROS-dependent autophagy in MOLT-4 acute lymphoblastic leukemia cells at 24 h by upregulating autophagy-related genes and genes in the Sirt1-Bnip3-FoxO3a pathway; in addition, autophagy acts as a survival pathway, and inhibition of autophagy enhances Ergolide-induced apoptosis^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

RAW 264.7 macrophages (LPS/IFN-γ-stimulated)
Concentration:

0.5-10 μM
Incubation Time:

18 h
Result:

Decreased iNOS protein levels in a concentration-dependent manner, with significant inhibition observed at 2, 5, and 10 μM.\n
Decreased COX-2 protein levels in a concentration-dependent manner, with significant inhibition observed at 2, 5, and 10 μM.

Cell Cycle Analysis^[5]

Cell Line:

Human leukemic cell lines (Nalm6, MOLT-4); non-tumorous PBMC
Concentration:

0-6 μM (cell cycle analysis); 4 μM (qRT-PCR for gene expression)
Incubation Time:

48 h (cell cycle analysis; qRT-PCR for gene expression)
Result:

Induced G0/G1 phase arrest in Nalm6 and MOLT-4 cells, with no significant arrest in non-tumorous PBMC.
Increased mRNA expression of p21 and p27 in Nalm6 and MOLT-4 cells:
Nalm6 p21: ~4.5-fold change,
Nalm6 p27: ~2.8-fold change,
MOLT-4 p21: ~3.2-fold change,
MOLT-4 p27: ~2.7-fold change.
Increased Sub-G1 population (apoptotic cells) in Nalm6 and MOLT-4 cells.

Apoptosis Analysis^[5]

Cell Line:

Human leukemic cell lines (Nalm6, MOLT-4)
Concentration:

2-6 μM (8 h ROS measurement; 48 h apoptosis analysis); 4-6 μM with 10 mM NAC pre-treatment (8 h ROS measurement, 48 h cell death assay); 6 μM (48 h Bax/Bcl-2 gene expression)
Incubation Time:

8 h (ROS measurement); 48 h (apoptosis analysis, cell death assay, gene expression)
Result:

Dose-dependently increased ROS levels in Nalm6 (up to 2-fold) and MOLT-4 (up to 4-fold) cells; NAC pre-treatment abrogated ergolide-induced ROS accumulation and reduced cell death in MOLT-4 cells.

Dose-dependently increased apoptotic cell death:
Nalm6: ~80% cell death at 6 μM,
MOLT-4: ~40% cell death at 6 μM.

Increased Bax mRNA expression (~3.8-fold change) and decreased Bcl-2 mRNA expression (~0.3-fold change) in Nalm6 cells treated with 6 μM ergolide; similar changes observed in MOLT-4 cells.

In Vivo

Ergolide (2.5 μM; 3 d) exerts significant in vivo anticancer effects in a zebrafish OMM2.5 xenograft model, reducing the normalized mean fluorescence of primary xenografts by 56% without altering the number of disseminated cells^[1].
Ergolide (incubated in embryo culture medium; pre-treatment for 23.5 h + 30 min) increases the survival rate, restores sensorimotor function, and reduces the expression of il-1β in LPS-stimulated zebrafish larvae; however, it fails to alleviate pentylenetetrazol (PTZ)-induced epileptiform hyperactivity in zebrafish larvae at 15 mM^[2].
Ergolide (5-10 mg/kg; p.o.; once every 2 days; for 7 consecutive days) dose-dependently improves the survival rate of male C57BL/6J mice with sepsis, alleviates LPS-induced acute lung injury in wild-type mice in an NLRP3-dependent manner, but no protective effect is observed in NLRP3-knockout mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

WT-Tü Zebrafish (4-5 days post-fertilisation larvae; LPS-induced systemic inflammation model)^[2]
Dosage:

3 μM; 5 μM
Administration:

incubated in embryo media; 24 h total
Result:

Significantly increased the survival rate of LPS-challenged larvae compared to LPS alone at 5 μM.
Significantly restored the LPS-impaired touch startle response, increasing the proportion of larvae exhibiting an escape-like reflex movement at 5 μM.
Significantly reduced LPS-induced upregulation of il-1β mRNA expression in larvae at 5 μM, but did not alter LPS-induced increases in tnfα or il-8 mRNA expression.
Significantly increased tnfα mRNA expression in unchallenged larvae at 5 μM.

Animal Model:

C57BL/6J (male) mice^[3]
Dosage:

5 mg/kg; 10 mg/kg
Administration:

i.g.; every 2 days; 7 days
Result:

Showed a higher survival rate in the 10 mg/kg group than the 5 mg/kg group.
Prevented all mice from dying within 48 hours, with a portion surviving through the 72-hour observation period in both treated groups.

Animal Model:

C57BL/6J wild-type (male) mice; C57BL/6-Nlrp3^-/^- (NLRP3 knockout, male) mice^[3]
Dosage:

10 mg/kg
Administration:

i.g.; every 2 days; 7 days
Result:

Significantly reduced LPS-induced lung injury scores, myeloperoxidase (MPO) activity in lung tissue, lung wet/dry weight ratio, total cell count, total protein concentration, and neutrophil count in BALF, as well as IL-1β levels in serum and BALF in wild-type mice.
Reduced the expression of mature IL-1β and cleaved caspase-1 (P20) in wild-type mouse lung tissue.
Produced no significant beneficial effects in NLRP3 knockout mice.

Chemical Information

CAS No. 54999-07-4
Appearance Solid
Masse moléculaire 306.35
Formule C₁₇H₂₂O₅
Color White to off-white
SMILES

CC(O[C@@H]1[C@]2([C@](CCC2=O)([H])[C@H](C)C[C@@](O3)([H])[C@@]1([H])C(C3=O)=C)C)=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Plants
- Compositae
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (3)

All

Sort by:

Journal Impact Factor

Int J Mol Sci

Ergolide Regulates Microglial Activation and Inflammatory-Mediated Dysfunction: A Role for the Cysteinyl Leukotriene Pathway. [Abstract]

2025 May 23;26(11):5050. PMID: 40507859
Int Immunopharmacol

The protective effect of Ergolide in osteoarthritis: In vitro and in vivo studies. [Abstract]

2024 Jan 25:127:111355. PMID: 38157693
Open Research Europe

2023 Jun 8.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (163.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2642 mL

16.3212 mL

32.6424 mL

5 mM

0.6528 mL

3.2642 mL

6.5285 mL

10 mM

0.3264 mL

1.6321 mL

3.2642 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (291 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Sundaramurthi H, Tonelotto V, Wynne K, et al. Ergolide mediates anti-cancer effects on metastatic uveal melanoma cells and modulates their cellular and extracellular vesicle proteomes[J]. Open Research Europe, 2023, 3: 88.

[2]. Galvin DM, et al. Ergolide Regulates Microglial Activation and Inflammatory-Mediated Dysfunction: A Role for the Cysteinyl Leukotriene Pathway. Int J Mol Sci. 2025;26(11):5050. Published 2025 May 23. [Content Brief]

[3]. Ren M, et al. Ergolide covalently binds NLRP3 and inhibits NLRP3 inflammasome-mediated pyroptosis. Int Immunopharmacol. 2023;120:110292. [Content Brief]

[4]. Whan Han J, et al. Ergolide, sesquiterpene lactone from Inula britannica, inhibits inducible nitric oxide synthase and cyclo-oxygenase-2 expression in RAW 264.7 macrophages through the inactivation of NF-kappaB. Br J Pharmacol. 2001;133(4):503-512. [Content Brief]

[5]. Yami A, et al. Ergolide, a potent sesquiterpene lactone induces cell cycle arrest along with ROS-dependent apoptosis and potentiates vincristine cytotoxicity in ALL cell lines. J Ethnopharmacol. 2020;253:112504. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2642 mL	16.3212 mL	32.6424 mL	81.6060 mL
	5 mM	0.6528 mL	3.2642 mL	6.5285 mL	16.3212 mL
	10 mM	0.3264 mL	1.6321 mL	3.2642 mL	8.1606 mL
	15 mM	0.2176 mL	1.0881 mL	2.1762 mL	5.4404 mL
	20 mM	0.1632 mL	0.8161 mL	1.6321 mL	4.0803 mL
	25 mM	0.1306 mL	0.6528 mL	1.3057 mL	3.2642 mL
	30 mM	0.1088 mL	0.5440 mL	1.0881 mL	2.7202 mL
	40 mM	0.0816 mL	0.4080 mL	0.8161 mL	2.0402 mL
	50 mM	0.0653 mL	0.3264 mL	0.6528 mL	1.6321 mL
	60 mM	0.0544 mL	0.2720 mL	0.5440 mL	1.3601 mL
	80 mM	0.0408 mL	0.2040 mL	0.4080 mL	1.0201 mL
	100 mM	0.0326 mL	0.1632 mL	0.3264 mL	0.8161 mL

Keywords

Ergolide

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ergolide

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Autoimmune Disease Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Ergolide

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR)

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Ergolide Related Classifications

HY-N6893 Related Classifications